Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06683365 · ClinicalTrials.gov registry record · Phase 1
Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies
A Phase 1 study of Parkinson's Disease and Multiple System Atrophy, sponsored by Craig van Horne, MD, PhD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 7
- Enrollment target
- 1
- Study location
NCT06683365: Recruiting Phase 1 study of Parkinson's Disease and Multiple System Atrophy, sponsored by Craig van Horne, MD, PhD.
NCT06683365 is a Phase 1 study of Parkinson's Disease and Multiple System Atrophy that is actively recruiting participants, run by Craig van Horne, MD, PhD. The registered enrollment target is 7 participants, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06683365, a Phase 1 study of Parkinson's Disease and Multiple System Atrophy, is actively recruiting participants, sponsored by Craig van Horne, MD, PhD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 7 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's disease (PD) or Multiple System Atrophy (MSA). 7 participants will be enrolled, with 4 participants receiving the graft and 3 receiving a sham surgery. Eligible participants will be early in their diagnosis with a lower burden of symptoms. Participants will be followed initially for one year after surgery.
Primary Outcome
Ability to recruit, enroll, and assign participants to the trial within 12 months of the trial opening.
Conditions Studied
Interventions
- PROCEDURE Sural Nerve Graft to the Substantia Nigra
- PROCEDURE Sham surgery
Study Locations (1)
Kentucky
- University of Kentucky - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2025-02-25 |
| Est. Completion | 2030-12-02 |
| Phase | Phase 1 |
What NCT06683365 shows while recruiting
NCT06683365 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 635-participant average among 158 other Parkinson's Disease trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Sural Nerve Graft to the Substantia Nigra is the first listed.
NCT06683365 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT06683365 about?
NCT06683365 is a clinical study titled "Autologous suraL nervE Grafting to the Substantia nigrA in Patients With Synuclienopathies". This phase I double-blind study focuses on the safety and feasibility of implanting autologous peripheral nerve tissue (PNT) into the substantia nigra area of the brain in persons who have been diagnosed with either Parkinson's disease (PD) or Multiple System Atrophy (MSA). 7 participants will be en...
What is the current status of trial NCT06683365?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2025-02-25. Estimated completion is 2030-12-02.
What conditions does trial NCT06683365 study?
This clinical trial studies the following conditions: Parkinson's Disease, Multiple System Atrophy.
What interventions are being tested in trial NCT06683365?
The interventions under investigation include: Sural Nerve Graft to the Substantia Nigra (PROCEDURE), Sham surgery (PROCEDURE).
Who is sponsoring clinical trial NCT06683365?
This trial is sponsored by Craig van Horne, MD, PhD, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06683365 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06683365's enrollment target sits among peer trials
7 153rd of 158 higher than 3 of 158 other Parkinson's Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson's Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
rTMS to Improve Cognition in Parkinson's
RECRUITING · Phase 1
-
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
RECRUITING · Phase 1
-
A Clinical Trial of LY3962681 in Healthy Volunteers and in Patients With Parkinson's Disease
RECRUITING · Phase 1
-
A Study to Evaluate Feasibility, Safety, and Clinical Responses of Implanting Autologous Peripheral Nerve Tissue Into the Brain for Non-motor or Motor Symptoms in Patients With Parkinson's Disease Undergoing DBS Surgery
RECRUITING · Phase 1
-
A Multicenter Study to Evaluate Safety, Tolerability, and Clinical Responses of DSP-1083 Into Subjects With Parkinson's Disease
RECRUITING · Phase 1
-
Feasibility and Safety of autoloGous UncondItioneD pEripheral Nerve Tissue Delivery to the Substantia Nigra (GUIDE)
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI